amending Decree No 532 / 2005 Coll., on the reimbursement of medicinal products and foodstuffs for special medical purposes, as amended by Decree No 37 / 2006 Coll.
The Ministry of Health provides pursuant to § 15 (10) (a) to (d) of Act No. 48 / 1997 Coll., on Public Health Insurance and on the amendment and addition of certain related laws, as amended by Act No. 438 / 2004 Coll.:
Annex No 1 to Decree No 532 / 2005 Coll., on the reimbursement of medicinal products and foodstuffs for special medical purposes, as amended by Decree No 37 / 2006 Coll., reads as follows:
"Annex No 1 to Decree No 532 / 2005 Coll.
Medicinal products, including individually prepared medicinal products, radiopharmaceuticals and transfusion products, and food for special medical purposes fully covered by health insurance, the amount of payments of active substances and the amount of food payments for special medical purposes
| Číslo řádku vyhlášky | Označení ATC a V06XX | Název léčivé látky | Cesta podání | Množství | Název jedn. | Úhrada v Kč | Omezení |
|
| 1 | Stomatologika |
|
| 1.1 | A01AA01 | fluorid sodný | p.o. | 1.10 | MG | 0,87 | |
| 46265 | ZYMAFLUOR 1/4 MG | portblnob200x0.25mg | FAJ | I |
| 1.2 | A01AB10 | natamycin | lok. | 20.00 | MG | 7,31 | |
|
| 1.3 | A01AB03 | chlorhexidin | lok. | 1 000.00 | ML | 174,64 | H |
|
| 1.4 | A01AC01 | triamcinolon | lok. | 1.00 | GM | 13,38 | L/DER,STO, ORL |
|
| 1.5 | A01AC02 | dexametason | lok. | 1.00 | GM | 11,41 | L/DER,STO, ORL |
| 2 | adsorbční antacida a protivředová léčiva ze skupiny H2-blokátorů, perorální podání |
|
| 2.1 | A02AD | kombinace hliníku, vápníku a hořčíku (pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.2 | A02AD | kombinace hliníku, vápníku a hořčíku (tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.3 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.4 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.5 | A02AD04 | hydrotalcit (pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.6 | A02AD04 | hydrotalcit (tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.7 | A02BA01 | cimetidin | p.o. | 0.80 | GM | 3,11 | |
|
| 2.8 | A02BA02 | ranitidin nad 75 mg v 1tbl | p.o. | 0.30 | GM | 3,11 | |
| 12346 | HISTAC 150 | tbl obd 20x150mg | RXY | IND |
| 14664 | HISTAC 150 | por tbl flm20x150mg | IRI | IRL |
| 2.9 | A02BA03 | famotidin 20 mg a výše v 1 tabletě | p.o. | 40.00 | MG | 3,11 | |
|
| 2.10 | A02BA04 | nizatidin | p.o. | 0.30 | GM | 3,11 | |
|
| 2.11 | A02BA06 | roxatidin | p.o. | 0.15 | GM | 3,11 | |
|
| 2.12 | A02BA07 | ranitidin bismut citrát | p.o. | 0.80 | GM | 27,85 | |
| 3 | protivředová léčiva ze skupiny inhibitorů protonové pumpy a ostatní protivředová léčiva |
|
| 3.1 | A02BA01 | cimetidin | parent. | 0.80 | GM | 31,33 | H |
|
| 3.2 | A02BA02 | ranitidin | parent. | 0.30 | GM | 66,88 | H |
|
| 3.3 | A02BA03 | famotidin | parent. | 40.00 | MG | 66,88 | H |
|
| 3.4 | A02BC01 | omeprazol | parent. | 20.00 | MG | 163,92 | H |
|
| 3.5 | A02BC01 | omeprazol (do 10 mg v jedné dávce včetně) | p.o. | 20.00 | MG | 12,60 | |
|
| 3.6 | A02BC01 | omeprazol (nad 10 mg v jedné dávce) | p.o. | 20.00 | MG | 7,54 | |
| 60160 | ULTOP | cps 14x20mg | KRK | SLO |
| 3.7 | A02BC02 | pantoprazol | p.o. | 40.00 | MG | 7,54 | |
|
| 3.8 | A02BC02 | pantoprazol | parent. | 40.00 | MG | 163,92 | H |
|
| 3.9 | A02BC03 | lansoprazol | p.o. | 30.00 | MG | 7,54 | |
|
| 3.10 | A02BC05 | esomeprazol (do 20mg v jedné dávce včetně) | p.o. | 30.00 | MG | 16,27 | L/GIT,INT,GER |
|
| 3.11 | A02BC05 | esomeprazol (nad 20mg v jedné dávce ) | p.o. | 30.00 | MG | 9,03 | L/GIT,INT,GER |
|
| 3.12 | A02BC05 | esomeprazol | parent. | 30.00 | MG | 163,92 | H |
|
| 3.13 | A02BX | ostatní léčiva peptického vředu (bismut subsalicylat) | p.o. | 3.00 | DF | 20,14 | |
|
| 3.14 | A02BX02 | sukralfát | p.o. | 4.00 | GM | 7,54 | |
|
| 3.15 | A02BX03 | pirenzepin | p.o. | 0.10 | GM | 7,54 | |
|
| 3.16 | A02BX03 | pirenzepin | parent. | 20.00 | MG | 103,18 | H |
|
| 3.17 | A02BX05 | zásaditý citronan bismutitý | p.o. | 0.48 | GM | 20,85 | |
| 4 | spasmolytika, perorální podání |
|
| 4.1 | A03AA04 | mebeverin | p.o. | 0.30 | GM | 4,83 | |
|
| 4.2 | A03AA05 | trimebutin | p.o. | 0.30 | GM | 4,83 | |
|
| 4.3 | A03AB03 | oxyfenon | p.o. | 25.00 | MG | 2,25 | |
|
| 4.4 | A03AB06 | otilonium bromid | p.o. | 0.12 | GM | 12,14 | |
|
| 4.5 | A03AB11 | poldin | p.o. | 12.00 | MG | 2,25 | |
|
| 4.6 | A03AD01 | papaverin | p.o. | 0.10 | GM | 0,66 | |
|
| 4.7 | A03AD02 | drotaverin | p.o. | 0.10 | GM | 4,79 | |
| 17933 | NO-SPA FORTE | tbl 10x80mg | CPW | H |
| 4.8 | A03BA01 | atropin | p.o. | 1.50 | MG | 0,48 | |
|
| 4.9 | A03BB01 | butylskopolamin | p.o. | 60.00 | MG | 13,89 | |
| 5 | spasmolytika, ostatní cesty aplikace |
| |
| 5.1 | A03AD01 | papaverin | parent. | 0.10 | GM | 17,53 | |
|
| 5.2 | A03AD02 | drotaverin | parent. | 0.10 | GM | 24,97 | |
| 02552 | NO-SPA | inj 5x2ml/40mg | CHN | H |
| 5.3 | A03BA01 | atropin (1 mg a více v 1 ampuli) | parent. | 1.50 | MG | 8,09 | |
|
| 5.4 | A03BA01 | atropin (do 1mg v 1 ampuli) | parent. | 1.50 | MG | 14,81 | |
|
| 5.5 | A03BB01 | butylskopolamin | p.rect. | 60.00 | MG | 14,33 | |
|
| 5.6 | A03BB01 | butylskopolamin | parent. | 60.00 | MG | 36,77 | |
| 6 | anticholinergika a spasmolytika v kombinaci s analgetiky |
|
| 6.1 | A03DA | syntetická anticholinergika v komb. s analgetiky | p.o. | 2.00 | DF | 3,87 | |
|
| 6.2 | A03DA02 | pitofenon kombinace s analgetiky | p.rect. | 2.00 | DF | 13,70 | |
| 91517 | ALGIFEN SUP | rct sup 5 | LEX | CZ |
| 6.3 | A03DA02 | pitofenon kombinace s analgetiky | parent. | 2.00 | DF | 43,25 | |
|
| 6.4 | A03DA02 | pitofenon kombinace s analgetiky (pevné lékové formy) | p.o. | 2.00 | DF | 4,02 | |
|
| 6.5 | A03DA02 | pitofenon kombinace s analgetiky (tekuté lékové formy) | p.o. | 2.00 | ML | 5,69 | |
|
| 6.6 | A03EA | antispasmodika, psycholeptika, analgetika v komb. | p.rect. | 2.00 | DF | 12,43 | |
| 7 | prokinetika, antiflatulencia, perorální podání |
| |
| 7.1 | A03AE02 | tegaserod | p.o. | 12.00 | MG | 29,32 | |
|
| 7.2 | A03AX13 | silikony (pevné lékové formy) | p.o. | 0.50 | GM | 9,59 | |
|
| 7.3 | A03AX13 | silikony (tekuté lékové formy) | p.o. | 0.50 | GM | 16,33 | |
| 93500 | SAB SIMPLEX | sus 1x30ml | PDA | D |
| 7.4 | A03AX58 | alverin (kombinace se silikony) | p.o. | 0.18 | GM | 7,34 | |
|
| 7.5 | A03FA | itoprid | p.o. | 0.15 | GM | 24,70 | L/GIT,INT,PED |
|
| 7.6 | A03FA01 | metoclopramid hydrochlorid | p.o. | 30.00 | MG | 3,67 | |
| 56695 | MCP HEXAL 10 | tbl 50x10mg | SFS | D |
| 56696 | MCP HEXAL 10 | tbl 100x10mg | SFS | D |
| 7.7 | A03FA02 | cisaprid (pevné lékové formy, nad 10 mg v 1 tabletě) | p.o. | 30.00 | MG | 21,99 | L/GIT,INT,PED PSY, GER |
|
| 7.8 | A03FA02 | cisaprid (pevné lékové formy, nad 5 mg do 10 mg včetně v 1 tabletě) | p.o. | 30.00 | MG | 25,41 | L/GIT,INT,PED PSY, GER |
|
| 7.9 | A03FA02 | cisaprid (tekuté lékové formy dělené - sáčky) | p.o. | 30.00 | MG | 25,41 | L/GIT,INT,PED PSY, GER |
|
| 7.10 | A03FA02 | cisaprid (tekuté lékové formy) s obsahem 1 mg v 1 ml | p.o. | 30.00 | MG | 55,88 | L/GIT,INT,PED PSY, GER |
|
| 7.11 | A03FA03 | domperidon | p.o. | 30.00 | MG | 3,87 | |
|
| 7.12 | A03FA05 | alizaprid | p.o. | 0.15 | GM | 3,87 | |
| 8 | prokinetika, ostatní cesty aplikace |
|
| 8.1 | A03FA01 | metoclopramid | p.rect. | 30.00 | MG | 40,56 | |
|
| 8.2 | A03FA01 | metoclopramid | parent. | 30.00 | MG | 20,69 | O |
| 93105 | DEGAN | inj 50x2ml/10mg | LEK | SLO |
| 8.3 | A03FA02 | cisaprid | p.rect. | 30.00 | MG | 46,49 | |
|
| 8.4 | A03FA03 | domperidon | p.rect. | 0.12 | GM | 40,56 | |
|
| 8.5 | A03FA05 | alizaprid | parent. | 0.15 | GM | 16,10 | O |
| 9 | antiemetika, perorální podání |
|
| 9.1 | A04AA01 | ondansetron (pevné lékové formy do 4 mg v jedné tabletě včetně) | p.o. | 16.00 | MG | 428.61 | P |
| 15829 | EMESET- 4 | por tbl flm 6x4mg | SDD | CZ |
| 15830 | EMESET- 4 | por tbl flm 60x4mg | SDD | CZ |
| 84744 | EMESET- 4 | tbl obd 6x4mg | CIA | IND |
| 9.2 | A04AA01 | ondansetron (pevné lékové formy nad 4 mg v jedné tabletě) | p.o. | 16.00 | MG | 317.67 | P |
| 15831 | EMESET- 8 | por tbl flm 6x8mg | SDD | CZ |
| 9.3 | A04AA01 | ondansetron (tekuté lékové formy) | p.o. | 16.00 | MG | 671,14 | P |
|
| 9.4 | A04AA02 | granisetron | p.o. | 2.00 | MG | 317.67 | P |
|
| 9.5 | A04AA03 | tropisetron | p.o. | 5.00 | MG | 317.67 | P |
|
| 9.6 | A04AA04 | dolasetron | p.o. | 200.00 | MG | 317.67 | P |
Ondansetron, granisetron, tropisetron, dolasetron and palonosetron are paid for in patients with nausea and vomiting due to strong release of serotonin, induced by cytotoxic chemotherapy and radiotherapy.
| 9.7 | A04AD | různá antiemetika (meklozin) | p.o. | 50.00 | MG | 3,23 | |
|
| 9.8 | A04AD | různá antiemetika (theoklát embraminu) | p.o. | 50.00 | MG | 3,23 | |
|
| 9.9 | A04AD | různá antiemetika (theoklát moxastinu) | p.o. | 0.10 | GM | 3,23 | |
| 10 | antiemetika, ostatní cesty aplikace |
|
| 10.1 | A04AA | palonosetron | parent. | 1 | DF | 2 749,14 | P |
|
| 10.2 | A04AA01 | ondansetron (léková forma čípků) | p.rect. | 16.00 | MG | 553,61 | P |
|
| 10.3 | A04AA01 | ondansetron (do 4 mg v jedné ampuli včetně) | parent. | 16.00 | MG | 764,19 | P |
| 15827 | EMESET | inj sol 5x2ml/4mg | SDD | CZ |
| 84441 | EMESET | inj 5x2ml/4mg | CIA | IND |
| 10.4 | A04AA01 | ondansetron (nad 4 mg v jedné ampuli) | parent. | 16.00 | MG | 616,33 | P |
| 15828 | EMESET | inj sol 5x4ml/8mg | SDD | CZ |
| 10.5 | A04AA02 | granisetron | parent. | 3.00 | MG | 404,59 | P |
|
| 10.6 | A04AA03 | tropisetron (do 2,5 mg včetně v jedné ampuli) | parent. | 5.00 | MG | 696,37 | P |
|
| 10.7 | A04AA03 | tropisetron (nad 2,5 mg v jedné ampuli) | parent. | 5.00 | MG | 404,59 | P |
|
| 10.8 | A04AA04 | dolasetron | parent. | 100.00 | MG | 404,59 | P |
Ondansetron, granisetron, tropisetron, dolasetron and palonosetron are paid for in patients with nausea and vomiting due to strong release of serotonin, induced by cytotoxic chemotherapy and radiotherapy.
| 10.9 | A04AD01 | různá antiemetika (theoklát moxastinu) | p.rect. | 0.10 | GM | 9,17 | |
| 11 | hepatika a hepatoprotektiva a další léčiva působící na žlučové cesty nebo játra |
|
| 11.1 | A05AA01 | kyselina chenodeoxycholová | p.o. | 1.00 | GM | 20,97 | L/GIT,INF |
|
| 11.2 | A05AA02 | kyselina ursodeoxycholová | p.o. | 0.75 | GM | 21,99 | L/GIT,INF |
| 13808 | URSOSAN | por cpsdur100x250mg | PMP | CZ |
| 11.3 | A05AX | jiná léčiva onemocnění žlučníku (fenipentol) | p.o. | 3.00 | DF | 1,58 | |
|
| 11.4 | A05AX02 | hymekromon | p.o. | 1.20 | GM | 5,82 | |
|
| 11.5 | A05BA | léčiva onemocnění jater (fosfolipidy) | p.o. | 4.00 | DF | 10,31 | |
|
| 11.6 | A05BA | léčiva onemocnění jater (fosfolipidy) | parent. | 1.00 | DF | 41,75 | H |
|
| 11.7 | A05BA | léčiva onemocnění jater (silymarin v kombinaci) | p.o. | 0.21 | GM | 4,84 | |
|
| 11.8 | A05BA03 | silymarin | parent. | 0.35 | GM | 2 291,90 | H |
|
| 11.9 | A05BA03 | silymarin (do 70 mg včetně v jedné tabletě) | p.o. | 0.21 | GM | 4,84 | |
|
| 11.10 | A05BA03 | silymarin (nad 70 mg v jedné tabletě) | p.o. | 0.21 | GM | 3,87 | |
| 12 | laxativa a další léčiva k očištění střeva |
|
| 12.1 | A06AD10 | kombinace minerálních solí (k přípravě Golytelyho roztoku) | p.o. | 4.00 | DF | 237,19 | |
|
| 12.2 | A06AD11 | laktulóza | p.o. | 6.70 | GM | 3.30 | L/GIT,INT,GER, PED.CHI, ONK |
| 42547 | LACTULOSE AL SIRUP | por sir 1x500ml | APA | D |
| 81456 | DUPHALAC | por sir 1x500ml-hdp | SOO | NL |
| 12.3 | A06AD12 | laktitol | p.o. | 10.00 | GM | 3,30 | L/GIT,INT,GER, CHI |
|
| 12.4 | A06AD15 | macrogol | p.o. | 4.00 | DF | 237,19 | |
|
| 12.5 | A06AG10 | sorbitol v kombinaci s kont. laxativem | p.rect. | 2.00 | DF | 166,73 | |
| 92489 | YAL | sol 10x67.5ml | TRM | D |
| 13 | antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, perorální podání |
|
| 13.1 | A07AA01 | neomycin | p.o. | 5.00 | GM | 596,07 | H |
|
| 13.2 | A07AA02 | nystatin | p.o. | 1.50 | MU | 5,82 | |
|
| 13.3 | A07AA03 | natamycin | p.o. | 0.30 | GM | 40,08 | |
|
| 13.4 | A07AA11 | rifaximin | p.o. | 0.80 | GM | 83,07 | P |
Rifaximin is prescribed in the following indications:
(1) hepatic encephalopathy,
2) prophylaxis in colorectal surgery,
3) pseudomembranose colitis,
4) bacterial infection associated with non-specific inflammatory bowel disease (i. e. Crohn 's disease and ulcerative colitis) susceptible to rifaximin.
| 13.5 | A07BC05 | diosmectit (plv. susp.) | p.o. | 1.00 | DF | 3,77 | L/PED, INF |
|
| 13.6 | A07EA06 | budesonid | p.o. | 9.00 | MG | 93,66 | P |
Oral budesonide prescribes a gastroenterologist or internist in an acute attack, or chronic phase of Crohn 's disease, affecting ileum or colon ascendens, particularly where there is a need to treat steroids while minimising their systemic effects.
| 64786 | BUDENOFALK | cps ent 50x3mg | FAK | D |
| 13.7 | A07EB01 | natrium kromoglykát | p.o. | 800.00 | MG | 71,91 | P |
The sodium cromoglycate is prescribed by an allergologist and a clinical immunologist in evidence of food allergy accompanied by severe local or general symptoms which cannot be fully corrected by the elimination of food allergens, based on an allergenic examination of skin potential exposure test or a specific IgE of antibodies.
| 13.8 | A07EC01 | sulfasalazin | p.o. | 2.00 | GM | 14,80 | L/GIT,INT,REV, GER |
|
| 13.9 | A07EC02 | mesalazin (léková forma - sáčky) | p.o. | 1.50 | GM | 37.67 | P |
Mesalazine per os - pharmaceutical format- sachets is the first-choice aminosalicylate in non-specific intestinal inflammation (Crohn 's disease) affecting the upper gastrointestinal tract, small intestine and adjacent colon (ileocolitis) in children under 3 years of age and in patients with swallowing disorder. It is not a first-choice aminosalicylate for the location of non-specific intestinal inflammation in the colon; is indicated after failure of other aminosalicylates.
| 13.10 | A07EC02 | mesalazin (potahované tablety) | p.o. | 1.50 | GM | 22,56 | L/GIT,INT,GER |
| 15533 | ASACOL 400 | por tblflm100x400mg | MBO | CZ |
| 13.11 | A07EC02 | mesalazin (tablety uvolňováním) | s řízeným | p.o. | 1.50 | GM | 37.67 | P |
Mesalazine powder - modified-release tablets: is a first-choice aminosalicylate in non-specific intestinal inflammation (Crohn 's disease) affecting the upper gastrointestinal tract, small intestine and adjacent colon (ileocolitis). It is not a first-choice aminosalicylate for the location of non-specific intestinal inflammation in the colon, it is indicated here after failure of other aminosalicylates.
| 13.12 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), lékové formy tobolek | p.o. | 2.00 | DF | 24,57 | P |
Medicinal product containing anti-diarrhoea microorganisms (E.coli) is prescribed in maintenance therapy for non-specific intestinal inflammation (i. e. Crohn 's disease and ulcerative colitis).
| 66065 | MUTAFLOR 20MG | cps ent 20x20mg | ARP | D |
| 13.13 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), tekuté lékové formy | p.o. | 1.00 | DF | 42.99 | L/PED, INF |
|
| 13.14 | A07FA01 | organismy produkující kyselinu mléčnou, pevné lékové formy | p.o. | 4.00 | DF | 3,77 | L/PED,GIT,GER, INF |
|
| 13.15 | A07FA01 | organismy produkující kyselinu mléčnou, tekuté lékové formy | p.o. | 2.00 | ML | 3,47 | L/PED,GIT,GER, INF |
| 09159 | HYLAK FORTE | sol 1x100ml | MCK | D |
| 13.16 | A07FA02 | saccharomyces boulardii sicatus | p.o. | 1.00 | DF | 5,38 | P |
Medicinal products containing Saccharomyces boulardii sic. are prescribed for the treatment of infectious diarrhoea, prophylaxis and the treatment of diarrhoea in patients fed with gastric or enteral nutrition using a probe.
| 14 | antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, ostatní cesty aplikace |
|
| 14.1 | A07EA06 | budesonid | p.rect. | 2.00 | MG | 216,73 | L/GIT,INT, GER |
|
| 14.2 | A07EC | paraaminosalicylát sodný | p.rect. | 2.00 | GM | 45,15 | L/GIT |
|
| 14.3 | A07EC02 | mesalazin (čípky do 250 mg včetně) | p.rect. | 1.50 | GM | 108,77 | L/GIT |
|
| 14.4 | A07EC02 | mesalazin (čípky nad 250 mg) | p.rect. | 1.50 | GM | 93,87 | L/GIT |
|
| 14.5 | A07EC02 | mesalazin (enema) do 1 gm včetně v 1 lahvičce | p.rect. | 1.50 | GM | 222.00 | L/GIT |
|
| 14.6 | A07EC02 | mesalazin (enema) nad 1 gm v 1 lahvičce | p.rect. | 1.50 | GM | 60.00 | L/GIT |
| 15535 | ASACOL ENEMA 4 G | sus rec 1x100ml/4gm | MBO | CZ |
| 15536 | ASACOL ENEMA 4 G | sus rec 7x100ml/4gm | MBO | CZ |
| 15 | digestiva včetně enzymových přípravků |
|
| 15.1 | A09AA | enzymové přípravky (s pankreatinem, dle obsahu lipázy) | p.o. | 5 000.00 | U | 0,10 | |
|
| 15.2 | A09AA02 | multienzymy (dle obsahu lipázy: do 10 000U včetně v jedné tabletě nebo kapsli) | p.o. | 5 000.00 | U | 1,44 | P |
Multienzymes up to 10,000 lipase In one tablet, cystic fibrosis is prescribed for paediatric patients up to 10 kg of their body weight.
| 15.3 | A09AA02 | multienzymy (dle obsahu lipázy: nad 10 000 do 19 999 U v jedné tabletě) | p.o. | 5 000.00 | U | 0,10 | |
| 15.4 | A09AA02 | multienzymy (dle obsahu lipázy: 20 000U v jedné tabletě) | p.o. | 5 000.00 | U | 1,37 | P |
Multienzymes as gastro-resistant tablets containing 20,000 lipase In patients with an algic form of chronic pancreatitis, they are prescribed using at least one of the following methods: ERCP, EUS, CT, MRCP, peroperatively, in patients with pancreatic cancer and after pancreatic resection.
| 40378 | PANZYNORM FORTE-N | por tbl flm 30 | KRK | SLO |
| 40379 | PANZYNORM FORTE-N | por tbl flm 100 | KRK | SLO |
| 15.5 | A09AA02 | multienzymy (dle obsahu lipázy: nad 20000U v jedné tabletě) – formy mikropelet | p.o. | 5 000.00 | U | 1,91 | P |
Multienzymes in the form of micropellets are prescribed in patients with cystic fibrosis and chronic pancreatitis with at least one of the following methods: ERCP, EUS, CT, MRCP, peroperatively, in patients with pancreatic cancer and pancreatic resection.
| 14811 | KREON 25 000 | por cps dur 50 | SVP | D |
| 15.6 | A09AA02 | multienzymy (dle lipázy, nad 20.000 U v jedné tabletě) | p.o. | 5 000.00 | U | 0,10 | |
|
| 15.7 | A09AC01 | pepsin a kyselinotvorné látky | p.o. | 2.00 | DF | 0,10 | |
| 16 | insuliny krátkodobě působící |
|
| 16.1 | A10AB01 | insulin lidský rychle účinkující 100 U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
|
| 16.2 | A10AB01 | insulin lidský rychle účinkující 100 U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in people with defined visual impairment determined on the basis of ophthalmologist examination - decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction, which can clearly not be used by other applicators due to visual impairment.
| 16.3 | A10AB01 | insulin lidský rychle účinkující, lahv. | parent. | 40.00 | U | 16,73 | |
| 40876 | INSULIN-HM R | inj 1x10ml/1ku | ZEH | CZ |
| 16.4 | A10AB03 | insulin vepřový rychle účinkující – cartridge parent. | 40.00 | U | 21,50 | L/DIA |
|
| 16.5 | A10AB03 | insulin vepřový rychle účinkující – lahv. parent. | 40.00 | U | 16,11 | |
| 17 | insuliny střednědobě působící včetně kombinací |
|
| 17.1 | A10AC02 | insulin hovězí středně dlouze účinkující – cartridge | parent. | 40.00 | U | 21,11 | L/DIA |
|
| 17.2 | A10AC02 | insulin hovězí středně dlouze účinkující - lahv. | parent. | 40.00 | U | 11,72 | |
|
| 17.3 | A10AC03 | insulin vepřový středně dlouze účinkující | parent. | 40.00 | U | 12,35 | |
|
| 17.4 | A10AC30 | insulin kombinace zvířecí středně dlouze účinkující | parent. | 40.00 | U | 12,35 | |
|
| 17.5 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
|
| 17.6 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in people with defined visual impairment determined on the basis of ophthalmologist examination - decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction, which can clearly not be used by other applicators due to visual impairment.
| 17.7 | A10AD01 | insulin lidský kombinace středně a rychle účinného, lahv. | parent. | 40.00 | U | 16,73 | |
| 40878 | INSULIN-HM MIX30 | inj 1x10ml/1ku | ZEH | CZ |
| 18 | insuliny dlouhodobě působící |
|
| 18.1 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
|
| 18.2 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in people with defined visual impairment determined on the basis of ophthalmologist examination - decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction, which can clearly not be used by other applicators due to visual impairment.
| 18.3 | A10AC01 | insulin lidský středně dlouze účinkující, lahv. | parent. | 40.00 | U | 16,73 | |
| 40875 | INSULIN-HM NPH | inj 1x10ml/1ku | ZEH | CZ |
| 18.4 | A10AE01 | insulin lidský dlouhodobě účinkující | parent. | 40.00 | U | 16,73 | |
|
| 18.5 | A10AE02 | insulin hovězí dlouhodobě účinkující - lahv. | parent. | 40.00 | U | 11,72 | |
|
| 18.6 | A10AE30 | insulin kombinace zvířecí dlouhodobě účinkující | parent. | 40.00 | U | 12,35 | |
| 19 | analoga insulinů a insuliny používané k aplikaci pomocí insulinové pumpy |
|
| 19.1 | A10AB04 | insulin-lispro krátce působící, cartridge 100U/ML | parent. | 40.00 | U | 28,22 | P |
|
| 19.2 | A10AB04 | insulin-lispro krátce působící, lahv. | parent. | 40.00 | U | 27,64 | L/DIA |
|
| 19.3 | A10AB05 | insulin-aspart krátce působící, cartridge 100U/ML | parent. | 40.00 | U | 28,22 | P |
|
| 19.4 | A10AB05 | insulin-aspart krátce působící, lahv. | parent. | 40.00 | U | 27,64 | L/DIA |
|
| 19.5 | A10AB06 | insulin glulisin, cartridge 100U/ML | parent. | 40.00 | U | 28,22 | P |
The short- and medium-acting insulin analogue (insulin aspart, insulin lispro, insulin glulisine) is indicated as the 2nd choice in diabetic patients with insufficient compensation in 3 consecutive controls for the treatment of classic human insulin (HbA1c above 6,5% according to IFCC). Insulin analogues should be replaced by human insulin unless there is a demonstrable improvement in glycaemic control (a decrease in the mean HbA1c by at least 10% or a reduction in the frequency of hypoglycaemia) in 3 consecutive controls.
| 19.6 | A10AB01 | insulin lidský rychle účinkující pro aplikaci do insulinových pump | parent. | 40.00 | U | 28.56 | L/DIA |
| 28001 | VELOSULIN 100 IU/ML | inj sol 1x10ml/1ku | NOO | DK |
| 19.7 | A10AD04 | insulin lispro, kombinace středně a rychle účinného, cartridge | parent. | 40.00 | U | 28,22 | P |
|
| 19.8 | A10AD05 | insulin aspart, kombinace středně a rychle účinného, cartridge | parent. | 40.00 | U | 28,22 | P |
The combination of short to medium-acting insulin analogue is indicated as a 2-choice combination in diabetic patients with insufficient compensation in 3 consecutive conventional insulin therapy procedures (HbA1c above 6,5% according to IFCC). Insulin analogues are replaced by human insulins unless there is a demonstrable improvement in glycaemic control (a decrease in the mean HbA1c by at least 10% or a reduction in the frequency of hypoglycaemia) in 3 consecutive controls.
| 19.9 | A10AE04 | insulin glargin, dlouhodobě účinný, lahv. | parent. | 40.00 | U | 27,64 | P |
|
| 19.10 | A10AE04 | insulin glargin, dlouhodobě účinný, cartridge | parent. | 40.00 | U | 44.58 | P |
|
| 19.11 | A10AE05 | insulin detemir, dlouhodobě účinný, cartridge | parent. | 40.00 | U | 44.58 | P |
Long-acting insulin analogues are prescribed only as a 2nd choice in patients treated with intensified insulin therapy in diabetic centres or outpatient diabetes patients on the recommendation of a diabetes centre for whom treatment with an insulin pump is indicated (repeated hypoglycaemia, unsatisfactory diabetes, requiring long-term effective insulin multiple daily). Insulin analogues are not indicated.
| 20 | perorální antidiabetika ze skupiny biguanidů a glitazonů |
|
| 20.1 | A10BA02 | metformin hydrochlorid | p.o. | 2.00 | GM | 6.09 | |
| 06668 | METFIREX 500 MG | por tbl flm60x500mg | CHN | H |
| 23228 | METFIREX 1 G | por tblflm60x1000mg | CPW | H |
| 30294 | ADIMET | tbl obd 60x850mg | MCK | D |
| 30343 | METFORMIN AL 500 | por tbl flm30x500mg | APA | D |
| 30356 | METFORMIN AL 500 | por tbl flm60x500mg | APA | D |
| 30361 | METFORMIN AL 500 | por tblflm120x500mg | APA | D |
| 40001 | METFORMIN AL 850 | por tbl flm30x850mg | APA | D |
| 40155 | METFORMIN AL 850 | por tbl flm60x850mg | APA | D |
| 40174 | METFORMIN AL 850 | por tblflm120x850mg | APA | D |
| 41506 | METFIREX 850 MG | por tblflm120x850mg | CHN | H |
| 41507 | METFIREX 500 MG | por tblflm120x500mg | CHN | H |
| 58122 | DIAPHAGE 850 | por tbl flm50x850mg | SVS | CZ |
| 58123 | DIAPHAGE 850 | por tblflm100x850mg | SVS | CZ |
| 58124 | DIAPHAGE 500 | por tblflm100x500mg | SVS | CZ |
| 58125 | DIAPHAGE 500 | por tbl flm50x500mg | SVS | CZ |
| 64641 | ADIMET | tbl obd 30x850mg | MCK | D |
| 64642 | ADIMET | tbl obd 120x850mg | MCK | D |
| 20.2 | A10BA03 | buformin | p.o. | 0.20 | GM | 3,39 | |
|
| 20.3 | A10BD02 | metformin a glibenklamid - kombinace | p.o. | 3.00 | DF | 4,84 | |
|
| 20.4 | A10BD03 | metformin a roziglitazon v kombinaci 500 mg a 1 mg | p.o. | 1.00 | DF | 9,32 | P |
|
| 20.5 | A10BD03 | metformin a roziglitazon v kombinaci 500 mg a 2 mg | p.o. | 1.00 | DF | 17,12 | P |
|
| 20.6 | A10BD03 | metformin a roziglitazon v kombinaci 1000 mg a 2 mg | p.o. | 1.00 | DF | 18,64 | P |
|
| 20.7 | A10BD03 | metformin a roziglitazon v kombinaci 1000 mg a 4 mg | p.o. | 1.00 | DF | 34,25 | P |
Metformin and rosiglitazone in combination prescribes a diabetic in the second choice after metformin therapy for the treatment of patients with type 2 diabetes and obesity (BMI > 30 kg / m2) with insulin resistance, unless there is a demonstrable improvement in glycaemic control over the previous treatment (HbA1c > 6,5% / according to IFCC) in 3 consecutive controls.
| 20.8 | A10BF01 | akarboza | p.o. | 0.30 | GM | 10,03 | |
|
| 20.9 | A10BG02 | rosiglitason s obsahem 4 mg v jedné tabletě | p.o. | 1.00 | DF | 31.21 | P |
|
| 20.10 | A10BG02 | rosiglitason s obsahem 8 mg v jedné tabletě | p.o. | 1.00 | DF | 46,81 | P |
|
| 20.11 | A10BG03 | pioglitazon s obsahem 15 mg v jedné tabletě | p.o. | 1.00 | DF | 31,21 | P |
|
| 20.12 | A10BG03 | pioglitazon s obsahem od 30 mg do 45 mg v jedné tabletě včetně | p.o. | 1.00 | DF | 46,81 | P |
Thiazolidinedione derivatives are prescribed by a 2-choice diabetes specialist after metformin therapy for the treatment of patients with type 2 diabetes and obesity (BMI > 30 kg / m2) and with insulin resistance, where there is no evidence of improvement in glycaemic control (HbA1c > 6,5% / according to IFCC).
The indicated daily dose is 1 tbl rosiglitazone containing 4 mg or 8 mg or 1 tbl pioglitazone containing 15 mg, 30 mg or 45 mg.
| 21 | perorální antidiabetika ze skupiny sulfonylurey a meglitinidů, případně další antidiabetika |
|
| 21.1 | A10BB01 | glibenklamid (do 1 mg v jedné tabletě včetně) | p.o. | 10.00 | MG | 2,25 | |
|
| 21.2 | A10BB01 | glibenklamid (nad 1 mg v jedné tabletě) | p.o. | 10.00 | MG | 0,84 | |
|
| 21.3 | A10BB01 | glibenklamid (mikronizované formy, do 1,75 mg včetně v jedné tabletě) | p.o. | 7.00 | MG | 1,34 | |
| 94523 | GLUCOBENE 1.75 MG | tbl 120x1.75mg | MCK | D |
| 21.4 | A10BB01 | glibenklamid (mikronizované formy, nad 1,75 mg v jedné tabletě) | p.o. | 7.00 | MG | 0,84 | |
| 94525 | GLUCOBENE 3.5 MG | tbl 120x3.5mg | MCK | D |
| 21.5 | A10BB02 | chlorpropamid | p.o. | 0.37 | GM | 0,76 | |
|
| 21.6 | A10BB03 | tolbutamid | p.o. | 1.50 | GM | 2,27 | |
|
| 21.7 | A10BB04 | glibornurid | p.o. | 38.00 | MG | 4,68 | |
|
| 21.8 | A10BB05 | tolazamid | p.o. | 1.00 | GM | 2,43 | |
|
| 21.9 | A10BB07 | glipizid | p.o. | 10.00 | MG | 3,71 | |
|
| 21.10 | A10BB08 | gliquidon | p.o. | 60.00 | MG | 4.56 | |
|
| 21.11 | A10BB09 | gliklazid | p.o. | 0.16 | GM | 4.56 | |
| 31897 | GLICIREX | por tbl nob 60x80mg | RTT | D |
| 21.12 | A10BB09 | gliklazid, retardované lékové formy | p.o. | 2.00 | DF | 4.56 | |
|
| 21.13 | A10BB12 | glymepirid do 2 mg v jedné tabletě včetně | p.o. | 2.00 | MG | 4.56 | |
|
| 21.14 | A10BB12 | glymepirid nad 2 mg v jedné tabletě | p.o. | 2.00 | MG | 3.79 | |
|
| 21.15 | A10BX02 | repaglinid | p.o. | 1.00 | DF | 4,89 | L/DIA |
|
| 21.16 | A10BX03 | nateglinid | p.o. | 1.00 | DF | 4,89 | L/DIA |
| 22 | vitamin A nebo D včetně jejich kombinací, perorální podání |
|
| 22.1 | A11CA01 | retinol (vitamin A) | p.o. | 50.00 | KU | 1,09 | |
|
| 22.2 | A11CC01 | ergocalciferol (pevné lékové formy) | p.o. | 6.00 | KU | 0,53 | |
| 00353 | VITAMIN D SLOVAKOFARMA | cps 1x300ku | SLO | SK |
| 22.3 | A11CC01 | ergokalciferol (tekuté lékové formy, do 200 p.o. U/ml včetně) | | 6.00 | KU | 12,80 | |
|
| 22.4 | A11CC01 | ergokalciferol (tekuté lékové formy, nad p.o. 200 U/ml) | | 6.00 | KU | 0,74 | |
| 00716 | INFADIN | gtt 1x10ml /100mg | SLO | SK |
| 22.5 | A11CC02 | dihydrotachysterol | p.o. | 1.00 | MG | 16,74 | |
|
| 22.6 | A11CC03 | alfakalcidol do 0,50 rg včetně | p.o. | 1.00 | RG | 13,12 | P |
|
| 22.7 | A11CC03 | alfakalcidol nad 0,50 rg | p.o. | 1.00 | RG | 12,37 | P |
|
| 22.8 | A11CC04 | kalcitriol | p.o. | 1.00 | RG | 24,74 | P |
Alfakalcidol and calcitriol p.o. are prescribed by an internist, endocrinologist, urologist, pediatrician, rhematologist, orthoped, gynecologist, geriatr, nephrologist and physician in the dialysis unit in patients:
(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;
(b) induced by the treatment of glucocorticoids,
(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.
2. for the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).
3. with vitamin D resistant curvature.
5. With hypoparathyroidism or pseudo-hypoparathyroidism resistant to vitamin D and calcium.
| 22.9 | A11CC05 | cholekalciferol – pevné lékové formy | p.o. | 0.50 | MG | 1,02 | |
|
| 22.10 | A11CC05 | cholekalciferol – tekuté lékové formy | p.o. | 0.50 | MG | 3,71 | |
| 12023 | VIGANTOL | por gtt sol 1x10ml | MEC | D |
| 23 | vitamin A nebo D včetně jejich kombinací, ostatní cesty aplikace |
|
| 23.1 | A11CA01 | retinol (vitamin A) | parent. | 50.00 | KU | 10,16 | |
|
| 23.2 | A11CC07 | paricalcitolum | parent. | 2.50 | RG | 329,87 | O/P |
Paricalcitol is indicated in patients on dialysis if:
(a) the serum PHT concentration is greater than 400pg / ml despite treatment with calcitriol for 3 months;
(b) calcitriol (hypercalcaemia on calcitriol - greater than 2,7 mmol / l and hyperphosphatemia greater than 2,5 mmol / l; phosphocalcatic product greater than 6,5) fails,
(c) extraoseal calcification by advanced hyperparathyroidism.
Treatment conditions are:
(a) sonographically proven enlarged parathyroid organs,
(b) verified hemodialysis efficacy (Kt / V above 1,2);
(c) compliance of the patient with measures regulating serum phosphorus concentrations (dietotherapy, effective dialysis, preparation of phosphate binders in GIT).
| 16881 | ZEMPLAR 5 MCG/ML | inj sol 5x2ml | ABB | I |
| 23.3 | A11CC01 | ergokalciferol | parent. | 6.00 | KU | 0,74 | |
|
| 23.4 | A11CC04 | kalcitriol | parent. | 1.00 | RG | 154,69 | O/P |
Parenteral calcitriol is prescribed by an internist, an endocrinologist, a urologist, a pediatrician and a physician in a dialysis unit in patients:
(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;
(b) induced by the treatment of glucocorticoids,
(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.
2. for the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).
3. with vitamin D resistant osteomalacia.
4. with vitamin D and calcium-resistant hypoparathyroidism.
| 23.5 | A11CC05 | cholekalciferol | parent. | 1.00 | KU | 0,92 | |
| 11093 | VIGANTOL 50000 | inj 5x1 ml/1.25mg | MEC | D |
| 24 | soli vápníku, perorální podání |
|
| 24.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | p.o. | 0.50 | GM | 0,58 | |
|
| 24.2 | A12AA04 | uhličitan vápenatý (na obsah vápníku) tablety | p.o. | 0.50 | GM | 2,29 | |
| 70536 | TBL.CALCII CARBON.PRAEC.0.5 MVM | portblnob1000x0.5gm | MVM | CZ |
| 24.3 | A12AA04 | uhličitan vápenatý (na obsah vápníku), léková forma šumivé tablety | p.o. | 0.50 | GM | 2,29 | |
|
| 24.4 | A12AA04 | uhličitan vápenatý (na obsah vápníku), léková forma prášky | p.o. | 0.50 | GM | 2,29 | |
|
| 24.5 | A12AA07 | chlorid vápenatý (na obsah bezvodého chloridu vápenatého), tekuté lékové formy | p.o. | 0.20 | GM | 1,05 | |
|
| 24.6 | A12AA12 | octan vápenatý (na obsah vápníku) | p.o. | 0.50 | GM | 9,77 | |
| 25 | kombinace solí vápníku, perorální podání |
|
| 25.1 | A12AA20 | vápník (kombinace různých solí, na obsah vápníku) | p.o. | 0.50 | GM | 2,48 | |
|
| 25.2 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a do 5 mg cholekalciferolu v 1 dávce včetně | p.o. | 1.00 | DF | 3,19 | |
|
| 25.3 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a nad 5 mg cholekalciferolu v 1 dávce | p.o. | 1.00 | DF | 3,91 | |
|
| 25.4 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) nad 600 mg vápníku v 1 dávce | p.o. | 1.00 | DF | 6,36 | |
|
| 25.5 | A12AX | vápník v kombinaci s fluorem (fluorofosfat sodný) | p.o. | 1.00 | DF | 5,26 | L/INT,GYN,ORT, REV,GER |
|
| 25.6 | A12AX | vápník v kombinaci s fluorem (levoglutamid fluorofosfat) | p.o. | 1.00 | DF | 3,92 | L/INT,GYN,ORT, REV,GER |
|
| 25.7 | A12CX | jiné minerální produkty (na obsah vápníku) | p.o. | 0.50 | GM | 1,18 | |
| 99808 | BIOMIN H | plv 60x3gm(sÁČky) | BMN | SK |
| 26 | soli vápníku, ostatní cesty aplikace |
|
| 26.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | parent. | 3.00 | GM | 57,82 | |
|
| 26.2 | A12AA07 | chlorid vápenatý (na obsah vápníku) | parent. | 0.20 | GM | 2,95 | |
| 00409 | CALCIUM CHLORATUM BIOTIKA | inj 5x10ml 10% | HBS | SK |
| 27 | soli draslíku, perorální podání |
|
| 27.1 | A12BA | draslík (na obsah draslíku) | p.o. | 1.50 | GM | 2,38 | |
|
| 27.2 | A12BA | draslík v kombinaci s hořčíkem (na obsah draslíku) | p.o. | 1.00 | GM | 9,56 | |
|
| 27.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | p.o. | 3.00 | GM | 2,15 | |
| 13715 | KALNORMIN | por tbl pro 30x1 gm | ICN | H |
| 28 | soli draslíku, ostatní cesty aplikace |
|
| 28.1 | A12BA | draslík v kombinaci s hořčíkem | parent. | 1.00 | DF | 12,90 | O |
| 02132 | CARDILAN | inj 10x10ml | HBS | SK |
| 28.2 | A12BA | draslík v kombinaci s hořčíkem, léková forma infuzí | parent. | 250.00 | ML | 84,05 | O |
|
| 28.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | parent. | 3.00 | GM | 53.86 | O |
| 02486 | KALIUM CHLORATUM LÉČIVA 7.5% | inj 5x10ml 7.5% | ZEH | CZ |
| 29 | soli hořčíku a jiné minerální produkty, perorální podání |
|
| 29.1 | A12CC03 | glukonat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
|
| 29.2 | A12CC04 | citronan hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
|
| 29.3 | A12CC05 | aspartat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
|
| 29.4 | A12CC06 | mléčnan hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
|
| 29.5 | A12CC09 | orotat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
|
| 29.6 | A12CC30 | kombinace hořečnatých solí (na obsah hořčíku) | p.o. | 1.00 | GM | 11,74 | L/INT,NEU,PSY, GYN,GER |
| 18774 | MAGNESIUM 250 MG PHARMAVIT | por tbl eff 20 | BSQ | F |
| 99891 | MAGNESIUM 250 MG PHARMAVIT | por tbl eff 20 | CPW | H |
| 30 | soli hořčíku, ostatní cesty aplikace |
|
| 30.1 | A12CC02 | síran hořečnatý (koncentrace do 10 % včetně) | parent. | 1.00 | GM | 19,27 | O |
|
| 30.2 | A12CC02 | síran hořečnatý (koncentrace nad 10%) | parent. | 1.00 | GM | 9,16 | O |
| 00499 | MAGNESIUM SULFURICUM BIOT.20% | inj 5x10ml 20% | HBS | SK |
| 31 | soli fluoru, perorální podání | | | | | |
|
| 31.1 | A12CD01 | fluorid sodný | p.o. | 88.00 | MG | 5,15 | |
| 91080 | FLUOSSEN | por tbl ent 30x15mg | ICN | PL |
| 32 | ostatní léčiva ovlivňující trávicí systém |
|
| 32.1 | A08AA10 | sibutramin s obsahem 10 mg v jedné tabletě | p.o. | 15.00 | MG | 13,00 | P |
|
| 32.2 | A08AA10 | sibutramin s obsahem 15 mg v jedné tabletě | p.o. | 15.00 | MG | 9,33 | P |
Diabetologist prescribes sibutramine to patients with inadequately compensated type 2 diabetes mellitus (HbA1c above 6,5% according to IFCC) and to BMI above 35 kg / m2 who are diagnosed with diabetic dyslipidaemia requiring pharmacological treatment. The contraindication is ICHS or blood pressure above 145 / 90. Tolerance should be evaluated every 14 days after initiation of therapy (blood pressure and heart rate) for 3 months, efficacy after 3 months of treatment with sibutramine. Efficacy criteria for sibutramine therapy are a weight decrease of at least 5% of baseline body weight while improving glycaemic control (a decrease of at least 10% of HbA1c). If treatment is not effective, sibutramine is discontinued after 3 months. Sibutramine therapy is indicated for a maximum of 12 months.
| 32.3 | A08AB01 | orlistat | p.o. | 360.00 | MG | 9,33 | P |
Diabetologist prescribes orlistat for the treatment of obese type 2 and BMI patients above 35 kg / m2 with concurrently diagnosed arterial hypertension and / or dyslipidaemia and / or ischaemic heart disease in whom diabetes is not satisfactorily compensated (HbA1c above 6,5% according to IFCC) with existing antidiabetic medication. Efficacy of orlistat therapy is controlled after 3 months, the criterion is to improve glycaemic control (decrease in HbA1c by at least 10%) and weight decrease by at least 5% of baseline body weight. If treatment is not effective, administration of orlistat is discontinued after 3 months. Treatment is indicated for a maximum of 12 months.
| 32.4 | A11GA01 | kyselina askorbová (vitamin C) | parent. | 0.20 | GM | 3,43 | H |
|
| 32.5 | A14AB01 | nandrolon phenpropionát | parent. | 2.00 | MG | 3,04 | |
|
| 32.6 | A16AA01 | levokarnitin | parent. | 2.00 | GM | 348,72 | O |
|
| 32.7 | A16AA02 | ademetionin | p.o. | 1.00 | GM | 58,47 | P |
|
| 32.8 | A16AA02 | ademetionin | parent. | 0.50 | GM | 92,51 | O/P |
Ademethionine prescribes gastroenterologist, internist, infectionist and gynaecologist in the treatment of intrahepatic cholestasis in chronic hepatic and biliary inflammation of any etiology, including intrahepatic cholestasis in pregnancy and primary biliary cirrhosis.
| 12319 | TRANSMETIL 500 MG INJEKCE | inj pso Iqf 5x500mg | HOL | I |
| 32.9 | A16AB02 | imiglucerasa | parent. | 200.00 | U | 31 877,85 | O/P |
Immiglucerase is prescribed for the treatment of confirmed diagnosis of non-neuronopathic (type I) or chronic neuronopathic (type 3) Gaucher disease in people who have clinically significant non-neurological symptoms of this disease.
Non-neurological manifestations shall mean one or more of the following conditions:
- anaemia after elimination of other possible causes such as iron deficiency
- bone disease after excluding other possible causes such as vitamin D deficiency
Comments 0